Biological functions of nutraceutical xylan oligosaccharides as a natural solution for modulation of obesity, diabetes, and related diseases

Abdo, A. A. A., Zhang, C., Patil, P., Teng, C., Li, X. and Liang, X.

1,2,4 Beijing Advanced Innovation Centre for Food Nutrition and Human Health, Beijing Technology and Business University, Beijing 100048, China, 2 School of Food and Health, Beijing Technology and Business University, No. 11, Fucheng Road, Beijing 100048, China, 3 Beijing Engineering and Technology Research Centre of Food Additives, School of Food and Chemical Technology, Beijing Technology and Business University, Beijing 100048, China, 4 Department of Food Science and Technology, Ibb University, Ibb 70270, Yemen

Article history
Received: 24 November 2020
Received in revised form: 18 May 2021
Accepted: 11 August 2021

Abstract
Natural compounds have been used to regulate numerous metabolic dysfunctions such as obesity, diabetes, and dyslipidaemia. Xylan oligosaccharides (XOS) alleviate obesity, diabetes, and dyslipidaemia via the regulation of glucose and lipid metabolisms, and the modification of gut microbiota. Moreover, XOS is also shown to inhibit obesity, diabetes, and related metabolic disorders such as inflammation and oxidative stress, by regulating the related genes and enzymes that contribute to the respective disorders. The information currently available does not offer in-depth elucidation regarding the molecular mechanisms of action of XOS in controlling obesity, diabetes, and related metabolic disorders, thus remain to be elucidated. The present review discusses XOS and its mechanisms of action, and key roles in regulating obesity, diabetes, and related metabolic disorders, highlighting the potential use of this compound in the improvement of novel therapeutic approaches for the treatment of the aforementioned diseases.

Keywords
xyloligosaccharides, obesity, diabetes, dyslipidaemia, related diseases

Introduction
Accumulating evidences indicate that the consumption of natural compounds ameliorates metabolic disorders such as diabetes, obesity, and dyslipidaemia (Lim et al., 2016; 2018). The study of natural compounds over the years has demonstrated their therapeutic potentials and preventive effects in the management of the aforementioned diseases. Some studies even suggested that bioactive compounds influence the metabolism of the whole body via the regulation of food intake, glucose, and lipid metabolism (Samanta et al., 2015).

Xyloligosaccharides (XOS) constitute a group of naturally occurring molecules with increasing interest in the nutrition field. XOS are obtained from natural sources by the hydrolysis of lignocellulosic materials (LCMs) (Brienzo et al., 2016). Due to low molecular weight (MW) and water solubility, LCMs are often used in large-scale commercial applications, especially XOS, which are essential for human healthcare. The biological effects of XOS include anti-obesity, antidiabetes, and dyslipidaemia modulation (Lim et al., 2016; 2018; Long et al., 2019), anticancer (Aachary et al., 2015), anti-inflammatory, enhancement of calcium availability (Singh et al., 2015), antioxidant (Jagtap et al., 2017), immunoregulatory (Patel and Prajapati, 2015), anticoagulant, antihypertensive, and anti-Alzheimer activities (Zhang et al., 2018). In general, XOS that have two units of xylose or more have been shown to possess greater biological activities such as anti-obesity, as compared to xylose monosaccharide. Furthermore, the biological activities of XOS are highest as compared to the other oligosaccharides (Saville and Saville, 2018). Although several studies have confirmed the anti-obesity, antidiabetic, and related effects of XOS, the underlying mechanisms are yet to be elucidated. Based on the efficacy of XOS in relieving diabetes, obesity, and related diseases, the search for their natural sources is rapidly becoming a goal for the treatment of diabetics and obese patients.
Herein, we summarised the efficacy of XOS in the management of obesity, diabetes, and related diseases.

**XOS preparation**

XOS are prepared from a variety of agricultural residues such as corncobs and sugarcane bagasse (Carvalho et al., 2013), wheat waste (Faryar et al., 2015), mahogany and mango wastes (Gobinath et al., 2017), rice waste, and cotton and sunflower stalks (Kiran et al., 2013), and green coconut husks (Jayapal et al., 2014). Corncobs, barley straws, cotton stalks, and sugarcane bagasse are considered rich sources of XOS (Carvalho et al., 2013).

The preparation of XOS is divided into two steps. The first step or pre-treatment step involves xylan (hemicellulose) extraction, while the second step involves the hydrolysis of xylan into XOS. The pre-treatment step can be conducted by ultrasound (Antov and Đorđević, 2017), microwave extraction (Panthapulakkal et al., 2013), steam explosion (Álvarez et al., 2017), and alkaline extraction (Carvalho et al., 2013). In the second step, the xylans can be hydrolysed using autohydrolysis, chemical methods, or enzymatic methods. The autohydrolysis method involves the conversion of xylan to XOS at 140 - 220°C in the presence of water (Samala et al., 2012; Samanta et al., 2015) and slightly acidic conditions (Qing et al., 2013). In chemical methods, XOS are produced by hydrolysis of xylan using mineral acid solutions such as sulphuric acid, acetic acid, and hydrochloric acid. Typically, chemical methods may yield toxic substances and monosaccharides in the final product, in addition to XOS, with a broad degree of polymerisation (DP) (Jain et al., 2015). The enzymatic method is performed using xylanases (Samanta et al., 2015), with endo-1,4-β-xylanase being the common enzyme acting on the hydrolysis bond in internal xylan polymers (β-1,4-linked backbone) (Chapla et al., 2012). In contrast to the previous methods, this method exhibits numerous advantages such as is easy to control and specialised. In addition, it operates under moderate conditions, environmentally friendly, and generates fewer undesirable substances as compared to the other methods. Moreover, it does not require special equipment, and is common in XOS production, although it is expensive as compared to the chemical methods (Chapla et al., 2012). XOS preparation from LCMs is summarised in Figure 1A.

---

**Figure 1.** (A) Preparation of XOS from lignocellulosic materials, and (B) structures of xylan and XOS, modified from Brienzo et al. (2016) and Dodd and Cann (2009). α-4-Me-GluUA: α-4-methyl-glucuronic acid, XOS: xylooligosaccharides, X2: xylobiose, and X3: xylotriose.
Chemical structure and physicochemical properties of XOS

XOS consists of two to ten molecules of xylose linked by β-(1→4)-glycosidic bonds, namely xylobiose, xylotriose, or xylotetraose (Figure 1B) (Samanta et al., 2015), and the presence of other side groups such as acetyl groups, arabinofuranosyl residues, α-D-glucopyranosyl uronic acid, or its 4-O-methyl derivative associated with xylan (Figure 1B) (Aachary and Prapulla, 2011). XOS are obtained through the hydrolysis of xylan, which is extracted from LCMs that are produced from agricultural sources, and consist of three main components: hemicellulose, cellulose, and lignin (Samanta et al., 2015). Hemicellulose percentage in common LCMs is 14 - 36% (Ruiz et al., 2013). Xylan is the most common type of hemicellulose, consisting of β-1,3-linked xylose units in marine organisms (Konishi et al., 2012) or β-1, 4-linked xylose unit in plants (Samanta et al., 2015). The structure and function of xylan depend on the extraction method and its source (Jensen et al., 2013). Therefore, XOS activity varies according to the different sources of xylan. XOS are also naturally present at low concentrations in fruits, vegetables, bamboo, honey, and milk. Xylan is watersoluble with low caloric value and a sweet taste, i.e., about 40% sweetness as compared to sucrose. In food application, XOS are incorporated in a wide variety of food products such as beverages, dairy products, acid products, salad dressings, alcoholic beverages, functional foods, and sugarless or low-sugar confectionaries. XOS are generally recognised as safe (GRAS) by the Food and Drug Administration (FDA), and approved by other worldwide organisations for application in foods and pharmaceutical product formulations (Ibrahim, 2018).

Effects of XOS on obesity, diabetes, and related diseases

Effects of XOS on obesity

Obesity is a major public health concern, and considered an epidemic hazard (Mohamed et al., 2014). In April 2020, the World Health Organization (WHO) reported that the number of overweight and obese people reached 1.9 billion and > 650 million, respectively, globally. In addition, > 340 and 41 million children, aged > 5 and < 5 years, are overweight or obese, respectively (WHO, 2020; Paciência et al., 2021). These numbers are expected to increase by 33% over the next two decades as compared to the past three decades, which represents 51% of the population, incurring a healthcare cost of $549.5 billion (Finkelstein et al., 2012). The phenomenon is restricted to increased body weight, and linked to numerous comorbidities such as diabetes mellitus (DM), hypertension, dyslipidaemia, cardiac alterations, metabolic syndromes, cancers, neurological disorders, and lung diseases (Mohamed et al., 2014). Although several probable targets have been recently identified for obesity control, the search for new, cost-effective, and safe therapeutic approaches remains essential.

The anti-obesity properties of XOS have attracted the attention of the scientific community in recent years. Data from both human and animal studies indicated that XOS are effective in regulating body and adipose fat tissue weights via several mechanisms such as improving in the inhibition of fat deposition and gene expression of adipogenesis markers, inducing changes in the composition of gut flora, and regulating food intake and body lipids (Lim et al., 2016; 2018; Zhang et al., 2018; Saville and Saville, 2018; Long et al., 2019; De Freitas et al., 2019). The inconsistent effects in these experiments may be due to the differences in the XOS compositions, sources, and protocol treatments used.

The regulation of body weight is influenced via the impact of XOS on the intestinal microflora, which in turn influences the extraction of energy from the diet. The intestinal microflora mainly comprise of three phyla: Actinobacteria (Bifidobacteria), Firmicutes (Ruminococcus, Clostridium, Lactobacillus, and Eubacteria), and Bacteroidetes (Porphyromonas, Prevotella, and Bacteroides) (Azad et al., 2018). Firmicutes and Actinobacteria in intestinal microflora contain the majority of obesity-linked genes (Turnbaugh et al., 2009; Hansen et al., 2013). The proportion of Firmicutes in obese individuals is higher as compared to that of Bacteroidetes; moreover, the increase in Firmicutes/Bacteroidetes ratio was also observed in obese individuals (Kasai et al., 2015; Koliada et al., 2017). The growth promotion of Bifidobacterium also plays a crucial role in inhibiting the development of obesity (Zhang et al., 2020). Roseburia spp. and members of the Lachnospiraceae family are characterised as typical short-chain fatty acids (SCFAs)-producing bacteria (Jefferson and Adolphus, 2019). Hansen et al. (2013) noted that 10% XOS supplementation into diet promoted SCFAs production in the gut of mice. It was speculated that
SCFAs protect against obesity by promoting the release of gut hormones such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), and influence lipid metabolism (Canfora et al., 2015; Zhao et al., 2017). Several experiments suggested that XOS alleviate obesity-related phyla such as Firmicutes and Firmicutes/Bacteroidetes ratio; correspondingly, XOS augmented Bacteroidetes, Bifidobacterium, Lactobacillus NK4A136 group, and Roseburia (Long et al., 2019; Zhang et al., 2020). In vitro and in vivo studies showed that XOS from different sources and structures regulated the bacteria related to obesity, especially the Bifidobacterium genus, with increasing SCFA production (Faryar et al., 2015; Gobinath et al., 2017; Jagtap et al., 2017). On the other hand, the decreased food intake due to XOS could be attributed to improved circulating leptin release from adipocytes that promotes satiety. In addition, XOS treatment enhanced adiponectin hormone (Lim et al., 2018) which is inversely associated with obesity via lipid metabolism. XOS also suppressed fat accumulation, adipose tissue weights (mesenteric, subcutaneous, and perirenal deposits), and fat mass in the liver by regulating the expression of genes associated with adipogenesis and lipogenesis (Lim et al., 2018; Long et al., 2019). Furthermore, XOS also attenuated obesity via the reduction of ceramide and diacylglycerol in the plasma due to lipogenesis regulation by XOS (Boini et al., 2018; Zhang et al., 2020). Similar results were observed by wheat-bran arabinoxylan-oligosaccharides that reduced the plasma ceramide levels in overweight human subjects (Benítez-Páez et al., 2019). Therefore, these findings indicated that XOS could be used as a nutraceutical for obesity treatment. The potential mechanisms of XOS against obesity are summarised in Figure 2.

**Figure 2.** Probable mechanism of anti-obesity action of XOS in obesity models. SCFAs: short-chain fatty acids, and XOS: xylooligosaccharides.

**Effects of XOS on diabetes**

DM is a metabolic disorder characterised by high plasma glucose levels caused by inappropriate secretion of insulin (type 1 DM or T1DM) or action of insulin (type 2 DM or T2DM). Currently, DM is a critical health problem worldwide, and the main risk for hypertension, cardiovascular diseases, respiratory diseases, and other complications that lead to mortality (Lee et al., 2016).

The application of XOS in the management of diabetes has been studied using several types of diabetic models. Currently, there are several reports on the antidiabetic activity of XOS. A study showed that XOS fed for six weeks attenuated hyperglycaemia in streptozotocin-induced diabetic rats by reducing nephromegaly, and lowering the advanced glycation end products (AGEs) (Gobinath et al., 2010). Another study unveiled that XOS attenuated the peripheral insulin resistance in obese-insulin resistant rats through the gut-brain axis (Chunchai et al., 2018). Furthermore, the consumption of XOS (DP 2 - 4) for 12 weeks alleviated glucose intolerance in mice fed a high-fat diet (HFD). This alleviation was due to the ability of
XOS in modifying gut flora and ceramide rise (Zhang et al., 2020). Previous studies also reported an association between impaired homeostasis of glucose and escalated ceramide levels in T2DM (Benítez-Páez et al., 2019).

The antidiabetic effect of xylobiose (a major disaccharide in XOS) has also been assessed in normal mice and diabetic db/db mice (the most extensively used mice model of T2DM) throughout six weeks. This administration of xylobiose successfully suppressed the improvement of hyperglycaemia in db/db mice. The antidiabetic action of xylobiose in this study regulated plasma glucose (Lim et al., 2016). In addition, the antidiabetic effect of xylobiose in obese mice also increased the insulin levels (Lim et al., 2018). Furthermore, the administration of D-xylose, a monosaccharide of XOS, also influenced insulin and blood glucose levels in obese mice; the mechanism by which D-xylose alleviated DM was the suppression of sucrase activity (Lim et al., 2015; 2016; 2018). The same mechanism was observed using the human models (Bae et al., 2011), proposing that the antidiabetic influence of XOS was also conferred to their monosaccharides. The efficiency of XOS in managing plasma glucose has also been evaluated in humans. A dosage of 2 gm/d XOS for eight weeks altered the intestinal microflora and insulin levels in pre-diabetic subjects (Yang et al., 2015). Furthermore, XOS consumption by T2DM subjects lowered the glucose, and managed the abnormal lipid metabolism (Zhu et al., 2019). In another study, XOS derived from rice husk exhibited antidiabetic efficacy by attenuating endotoxemia, and reducing the level of lipopolysaccharide (LPS) in diabetes plasma; whereas the presence of LPS in plasma was recognised as metabolic endotoxemia, which is linked to numerous diseases, specifically T2DM and obesity. Moreover, paracellular transport is a key function of several diseases, such as DM. XOS lessened the impaired intestinal paracellular permeability by decreasing the levels of fluorescein isothiocyanate-dextran in rat plasma. Furthermore, the glucose uptake surged in skeletal muscle (Khatudomkiri et al., 2019). Together, these findings proposed that XOS could be used as a natural agent for the management of DM. Figure 3 shows the summary of the mechanisms of action of XOS against diabetes.

**Figure 3.** Potential principal mechanisms of anti-diabetes action of XOS in diabetes models. SCFAs: short-chain fatty acids, and XOS: xylooligosaccharides.

**Effects of XOS on obesity- and diabetes-related diseases**

**Effects of XOS on dyslipidaemia**

An upsurge in the levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) or high-density lipoprotein cholesterol (HDL-C) is defined as dyslipidaemia or hyperlipidaemia (He et al., 2011; El-Tantawy and Temraz, 2018), which is responsible for an increased risk of heart diseases, atherosclerosis, and
cardiovascular diseases (Dake and Sora, 2016). Overall, a healthy diet has beneficial effects on regulating the profiles of serum lipid: reducing the TC, TG, and LDL-C (the bad cholesterol), while enriching the HDL-C (good cholesterol). A healthy diet may include decreased intake of dietary cholesterol and saturated and trans-fatty acids, and increased intake of functional foods and nutraceuticals (Chen et al., 2014).

The mechanism of dyslipidaemia modulation by XOS is to regulate lipid metabolism. XOS demonstrated TG- and cholesterol-lowering activities by enhancing mRNA expression of cholesterol 7-alpha-hydroxylase (CYP7A1), sterol 12-alpha-hydroxylase (CYP8B1), and ATP-binding cassette transporter G5/G8 (ABCG5/8) enzymes that enhance bile acid syntheses from cholesterol (Li et al., 2013; Lim et al., 2016). In contrast, XOS suppressed sterol regulatory element-binding protein (SREBP) that leads to the formation of enzymes involved in the synthesis of cholesterol such as HMG-CoA reductase (HMGCR) and hydroxyl-methylglutaryl-coenzyme A (HMG) synthase. XOS also suppresses the expression of SREBP-2 mRNA via liver X receptor alpha (LXR-α), an oxysterol receptor that stimulates ATP-binding cassette transporter (ABCG1/5/8), thus diminishing the level of HMGCR to yield less free cholesterol and other lipogenic genes including fatty acid synthase (FAS), sterol regulatory element-binding protein-1C (SREBP), acetyl-CoA carboxylase (ACC), and peroxisome proliferator-activated receptor gamma (PPAR-γ); all were regulated by XOS feeding (Lim et al., 2016; 2018). Another study found that XOS attenuated dyslipidaemia in obese-insulin resistant rats through the gut-brain axis (Chunchai et al., 2018). In obese mice, XOS supplementation levels alleviated plasma ceramides and diacylglycerol (DAG) levels via lipogenesis (Zhang et al., 2020). In human studies, HDL-C levels were increased in healthy subjects by feeding 8 gm/day XOS (Childs et al., 2014). The atherogenic index (AI) values were associated with atherogenic profiles, namely apolipoprotein B (ApoB), containing small LDL particles and lipoproteins. However, plasma TG and HDL-C independently represent risk factors for coronary diseases, whereas the AI formula that uses both the aforementioned factors, for example, log (TG/HDL-C), is useful and precise in predicting the atherogenicity of plasma. XOS decreased the AI values in obese mice (Lim et al., 2018). The mechanisms of the XOS action on dyslipidaemia regulation are depicted in Figure 4.


**Effects of XOS on inflammation**

Obesity or diabetes induces pro-inflammatory cytokine production and low-grade chronic systematic inflammation. The adipose tissues are a major source of interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), and resistin; these cytokines are
driven by HFD or lipid infusion. TNF-α levels are higher in the serum of obese individuals, thus releasing fatty acids into circulation by boosted adipose tissue lipolysis than in non-obese controls (Lim et al., 2018). Various concentrations and structures of XOS have anti-inflammatory effects. Long et al. (2019) showed a decrease in monocyte chemoattractant protein-1 (MCP-1) in obese mice after 2 and 7% doses of XOS, respectively. On the other hand, a 10% XOS (DP 2 - 6) consumption by male C57BL/6NTac mice for ten weeks downregulated interferon-gamma (IFN-γ) and the low-grade inflammatory cytokine IL-1β, thereby decreasing systemic inflammation. The underlying mechanism is an increase in SCFA concentrations by XOS supplementation (Hansen et al., 2013). Furthermore, D-xylose and xylobiose treatments lowered the pro-inflammatory cytokine expressions including MCP-1, TNF-α, and IL-1β (Lim et al., 2018). Under diabetic conditions, the increased production of inflammatory cytokines led to insulin resistance, which is linked to diabetes; XOS addition inhibits the levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, and MCP) and other genes related to inflammatory response including cyclooxygenase-2 (COX-2) and nitric oxide synthase (iNOS) (Lim et al., 2016). Moreover, mitogen-activated protein kinases (MAPKs) are triggered in response to various stimuli including inflammatory signals, stress, and ultraviolet irradiation (Tarantino and Caputi, 2011). p38MAPK phosphorylation is shown to stimulate the pro-inflammatory cytokines (TNF-α, IL-1β, and MCP). Thus, it could be hypothesised that XOS inhibited MAPKs phosphorylation in the liver of db/db mice, and also inactivated the MAPK pathway. Additionally, the inhibition of inflammatory response was consistent with the reduced blood glucose level (Lim et al., 2016). The mechanisms of inflammation regulation by XOS are summarised in Figure 5.

**Figure 5.** Mechanisms of the role of XOS in attenuating inflammation and oxidative stress in obesity or diabetes models. ACO: acyl CoA oxidase, CAT: catalase, COX-2: cyclooxygenase-2, CPT1A: carnitine palmitoyltransferase 1-A, GPX: glutathione peroxidase, HSL: hormone-sensitive lipase, IL-1β: low-grade inflammatory cytokine interleukin-1β, IL-6: interleukin-6, iNOS: nitric oxide synthase, MCP: monocyte chemoattractant protein, SOD: superoxide dismutase, TNF-α: tumour necrosis factor-α, and XOS: xylooligosaccharides.

**Effect of XOS on oxidative stress**

In diabetes, both blood glucose elevation and glucose oxidation give rise to large amounts of free radicals, thus resulting in enhanced activities and expression levels of antioxidant enzymes including superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase (CAT). The increased levels of blood glucose in diabetes are accompanied by an escalation in expression levels of these antioxidant enzymes, which may be associated with an increase in oxidative stress (Lim et al., 2016). Under diabetic conditions, oxidative stress also produces AGEs
The addition of XOS significantly improved the antioxidant enzymes and AGEs in the diabetic model (Gobinath et al., 2010; Samanta et al., 2015; Lim et al., 2016; De Freitas et al., 2019). Fascinatingly, the lipid oxidation-related gene, PPAR-γ, was downregulated by XOS treatment (Lim et al., 2016). XOS alone or amalgamated with probiotics attenuated hippocampal oxidative stress of HFD-fed rats (Chunchai et al., 2018). In addition, XOS administration significantly improved GPX and CAT levels in diabetic rats' blood (Gobinath et al., 2010). Remarkably, 5% XOS supplementation to rats fed HFD alleviated malondialdehyde (oxidative stress biomarker) levels in the heart, liver, and serum. In contrast, glutathione (GSH), a major antioxidant, glutathione disulphide, and primary antioxidant enzymes (SOD, CAT, and GPX) were augmented in the above organs (Wang et al., 2011). Overall, the activity of XOS against free radicals also depends on the bound phenolic content in the former structure, which was affected by their sources (Singh et al., 2015). For example, the antioxidant activity of XOS prepared from ragi was stronger than that prepared from rice, wheat, and maize (Jagtap et al., 2017). Furthermore, the antioxidant activity of garlic straw xylan XOS was equal to that presented by XOS derived from rice (Kallel et al., 2014). The regulatory mechanisms of XOS-mediated oxidative are summarised in Figure 5.

Conclusion

The present review proposed that XOS could be beneficial for the prevention of obesity, diabetes, and the related diseases, without the side effects often caused by chemical therapies. However, some future studies need to address, including but not limited to, multiple concentrations of XOS to assess the concentration-response results, separation of individual XOS and compare the effect for short and long study durations, and combination of XOS with various oligosaccharides that may provide synergistic effects on disease regulation. Furthermore, additional studies are needed to examine the effect of XOS on microbiota under diabetes. Also, animal studies are needed to understand the capacity of short-chain XOS in energy metabolism regulation, while clinical studies are needed to confirm the animal results and examine the long-term health consequences.

Acknowledgement

The present review was financially supported by the National Key Research and Development Program of China (grant no.: 2017YFD040020601); the National Natural Science Foundation of China (grant no.: 31830069, 31671798, 31701592); the Science and Technology Program of Beijing Municipal Education Commission (grant no.: KM202010011007); and the Science and Technology Innovation Service Ability—Construction of Provincial-level Scientific Research Platforms, Beijing Food Nutrition and Human Health Advanced Innovation Centre (grant no.: 19008020101).

References


activation through gut-brain axis by prebiotics, probiotics, or synbiotics effectively restored cognitive function in obese-insulin resistant rats. Journal of Neuroinflammation 15(1): article no. 11.


De Freitas, C., Carmona, E. and Brienzo, M. 2019. Xylooligosaccharides production process from lignocellulosic biomass and bioactive effects. Bioactive Carbohydrates and Dietary Fibre 18: article ID 100184.


Koliada, A., Syzenko, G., Moseiko, V., Budovska, L., Puchkov, K., Perederiy, V., … and Vaiserman, A. 2017. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiology 17(1): article no. 120.


Lim, E., Lim, J., Kim, E., Kim, Y.-S., Shin, J.-H., Seok, P. and Kim, Y. 2016. Xylobiose, an alternative sweetener, ameliorates diabetes-related metabolic changes by regulating
hepatic lipogenesis and miR-122a/33a in db/db mice. Nutrients 8(12): article no. 791.


induced obesity and glucose intolerance and modulate plasma lipid profile and gut microbiota in mice. Journal of Functional Foods 64: article ID 103622.
